4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

Background: Optimal timing for catheter ablation of ventricular tachycardia is an important
unresolved issue. There are no randomized trials evaluating the benefit of ablation after the …

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium
not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a …

Background: Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time
of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical …

The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

A organização de uma diretriz clínica é tarefa complexa, que necessariamente deve
envolver planejamento prévio, coordenação apropriada, revisão aprofundada da literatura …

Background: Chagas disease, resulting from the protozoan Trypanosoma cruzi, is an
important cause of heart failure, stroke, arrhythmia, and sudden death. Traditionally …

Background Recent advances have enabled noninvasive mapping of cardiac arrhythmias
with electrocardiographic imaging and noninvasive delivery of precise ablative radiation …